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The successful results seen after organ transplantation are largely attributable to 
the potency and specificity of modern immunosuppressive agents. Although 
drug-free unresponsiveness to graft alloantigens has not been routinely 
achieved in clinical practice, recent appreciation of the importance of cell 
chimerism, which develops after the migration from donor to host of leuko-
cytes contained in solid organ grafts, has introduced a concept which may 
explain the mechanism of graft tolerance. Recent evidence has indicated that 
immunosuppressive drugs may have a common potential to induce graft 
tolerance, even though they act through diverse mechanisms, and that this 
potential may be lnediated by a permissive effect on the rnigration and survival 
of donor-derived leukocytes. This review briefly examines the mechanisms by 
which immunosuppressive drugs function and analyses the different methods 
which these agents might use to induce chimerism associated with graft 
tolerance. Furthermore, we describe ongoing clinical studies in which the 
chimerism produced after solid organ transplantation is augmented with donor 
bone marrow in an attempt to facilitate the induction of tolerance. 
bone marrow transplantation, chimerism, immunosuppression, Immuno-
suppressive agents, organ transplantation, tolerance 
The use of immunosuppressive drugs to prevent or 
control graft rejection has revolutionised the outcome 
of transplantation surgery. Even so, complications of 
immunosuppression and side-effects associated with 
these agents remain significant risks for transplant 
patients. The idea of inducing 'drug-free' actively 
acquired tolerance was initially proposed and demon-
strated in animals by Billingham, Brent & Medawar in 
1953 (1). Although the ability to routinely induce drug-
free unresponsiveness to alloantigens expressed on 
organ grafts remains out of reach in clinical transplan-
tation, some recently developed concepts have 
increased our understanding of the circumstances that 
may predispose to tolerance induction and provide a 
foundation on which techniques to induce tolerance 
might be designed. 
new hypothesis has been proposed based on the recent 
appreciation of donor cdl chimerism persisting up to 30 
years after solid organ transplantation (4-7). The 
essence of this hypothesis is the permissive effect of all 
immunosuppressants on leukocyte migration between 
graft and host, ultimately allowing the establishment of 
stable cell chimerism (8-11). This paper discusses poss-
ible mechanisms by which drugs and other xenobiotics 
might permit chimerism and tolerance to occur. While 
relating the actions of these chemically diverse pharma-
cological agents to the chimerism associated with allo-
graft tolerance, we discuss the mechanisms which may 
be necessary for the induction of permanent donor-
specific unresponsiveness. 
We shall consider the concept that the first step in 
tolerance induction may be the initiation of a pharma-
cologically controlled two-way allogeneic response. 
Such attenuation of immune reactivity rna y permit the 
natural migration of passenger leukocytes from graft to 
host and their survival allowing the continuous re-
presentation of donor alloantigens to the recipient 
The current advanced state of rejection control has 
been attributed to the distinct molecular actions of the 
newer immunosuppressive agents (2,3). In addition, a 
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Table 1 Immunosuppressive drugs capable of inducing tolerance 
Agent Structure 
Deoxyspergualin semisynthetic polyamine 
Anti-CD4 monoclonal antibody 
Anti-LFA-1 " monoclonal antibody 
Anti-ICAM-I t monoclonal antibody 
Cyclosporine A cyclic peptide 
FK506 carboxy cyclic lactone 
Anti-IL-2R monoclonal antibody 
Rapamycin carboxycyclic lactone 
Azathioprine 6-mercaptopurine derivative 
Leflunomide isoxazole derivative 
Mizoribine imidazole nucleoside 
Mycophenolate mofetil mycophenolic acid derivative 
Cyclophosphamide nitrogen mustard derivative 
Brequinar sodium carboxylic acid derivative 
SK&F 105685 azaspirane analogue 
*LFA-1 = lymphocyte function-associated antigen-l 
tICAM-1 = intercellular adhesion molecule-I. 
under, as yet, poorly understood conditions that abro-
gate rejection and allow donor-specific unresponsive-
ness to occur. 
Pharmacological control of rejection 
Because of the extreme heterogeneity of agents that 
permit cell migration and chimerism to occur and that 
induce tolerance induction in appropriate experimental 
models, we will begin by briefly describing the bewil-
dering array of drugs and other therapeutic immuno-
suppressants. Rejection commences when an array of 
foreign antigens, especially products of the donor 
major histocompatibility complex (MHC), arc pre-
sented to host T-helper (Th) cells by graft antigen-
presenting cells (APC) (12). Although allografts disse-
minate a variety of 'passenger' cells (10,11), the cell 
primarily responsible for presentation of donor antigen 
has been shown to be the dendritic cell- the most potent 
of APC (13-15). 
Antigen presentation and the ensumg cascade of 
events leading to graft rejection can be inhibited at 
various levels by immunosuppressive agents. The 
agents which can effect such immunosuppression and 
their levels of action are portrayed in Table 1 and Fig. 1. 
These drugs act at many different stages of the immune 
response to allogeneic stimulation. Deoxyspergualin 
(DSG) is thought to induce immunosuppression and 
tolerance by inhibition of APC function (16), although 
it may also inhibit B cell mitogenesis and depress IL-2 
rt'ceptor expression on leukocytes. The subsequent 
induction of Til-cell activation and initiation of the 
rejection response requires that antigen is first presented 
by APC in the context of MHC class II gene products 
Level of action Reference 
macrophage function, cytotoxic T cells 16 
adhesion/accessory molecule expression 20 
adhesion/accessory molecule expression 19 
adhesion/accessory molecule expression 22 
inhibits IL-2 production 26 
inhibits IL-2 production 27 
inhibits IL-2 action 23 
inhibits IL-2 action 39 
inhibits DNA synthesis 40 
? B cell suppression 46 
inhibits DNA synthesis 42 
inhibits DNA synthesis 43 
inhibits DNA synthesis 41 
inhibits DNA synthesis 44 
? induction of suppressor cells 45 
and then recognized by the T-cell receptor (TCR). This 
interaction is facilitated by numerous accessory mol-
ecules and costimulatory factors, including several 
intercellular adhesion molecules. A variety of mono-
clonal antibodies (mAb) has been used to control rejec-
tion and induce tolerance in experimental animals by 
blocking the recognition or interaction of these mol-
ecules (sec Table 1) (17-23). Because of the T-cell-
mediated nature of allograft rejection, potent antiT -cell 
agents such as cyclosporine A (CsA) (24-26) and FK506 
(27-31) have demonstrated excellent results since being 
introduced to the field of transplantation. Unfortu-
nately, neither agent has induced tolerance in humans 
with the frequency seen in experimental organ trans-
plantation in rodents (26,27,32-34). Among their 
effects, both drugs inhibit the production of multiple 
cytokines (35-37) (but not IL-lO (38)), thereby con-
tributing to control of rejt'ction. Rapamycin is another 
powerful anti-T-cell agent capable of inducing toler-
ance in animals (39), however, results of ongoing phase 
I clinical trials are awaited before its wider introduction 
to clinical transplantation. 
Drugs such as azathioprine, cyclophosphamide, 
mizoribine, 111 ycophcnolate mofetil (previously known 
as RS61443) and brequinar sodium inhibit DNA syn-
thesis and cause immunosuppression by reducing the 
clonal proliferation which occurs after lymphocyte 
stimulation (40-44). SK&F 105685 and leflunomide are 
two recently described immunosuppressants which 
have the potential to join the clinical armamentarium of 
antirejection drugs (45,46). Briefly, preliminary results 
obtained with thest' agents suggest that each can signifi-
cantly prolong allograft survival in animal models 
(47,48) and may promote tolerance through the induc-
Monoclonal antibodies, 
DSG, MM 
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APe adhesion molecules: 
MHC class II, ICAM-1, 
ICAM-2, LFA-3, B7 
Th1, Th2 adhesion molecules: 
TCR/CD3, CD4, CD2, 
LFA-1, CD28 
Fig. 1 A diagrammatic representation 
of the immune response during rejection 
which demonstrates the principal sites 
of action of immunosuppressive drugs 
and monoclonal antibodies used to 
control anti-allograft responses. These 
agents also have the potential to induce 
tolerance. APC = antigen presenting 
cell; ThlITh2 = T-helper 1 or T-helper 
2 cell; T(cls) = T-(cytotoxiclsuppressor) 
cell; B = B-cell; IL-2R = IL-2 receptor. 
DSG = deoxyspergualin; MM = 
mycophenolate mofetil; CsA = 
cyclosporine A; Cy = 
cyclophosphamide; BQR = brequinar 
sodium. 
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tion of suppressor cell activity and B-cell suppression, 
respectively (45,46,49). 
Although the drugs described above show great 
chemical diversity, they arc all powerful immunosup-
pressive agents which arc either being investigated 
experimentally or used for the control of clinical graft 
rejection. Improvements in the control of rejection in 
the last decade have been attributed to newer and 
stronger immunosuppressive drugs acting at precise 
molecular levels (2,3,50). However, the purpose of this 
report is to suggest that allograft tolerance maybe 
secondary to a common effect of these drugs that allows 
the migration and survi val of donor-derived leukocytes 
which mav predispose to the establishment of periph-
eral T-cell tolerance (8-11,51). 
Donor-derived leukocyte migration - a 
phenomenon permitted by immunosuppressive 
agents 
The importance of the widespread migration of donor-
derived leukocytes and their survival after solid organ 
transplantation has only recentl y been appreciated (Fig. 
2). The cell migration seen is now believed to be a 
natural event which occurs after the transplantation of 
all organs, and the survival of these cells may be critical 
to long term graft survival (8-11,52-54). Although cells 
move both from host to graft and from graft to host, it 
is the latter pathway that appears to be of primary 
importance for the induction of tolerance. Migration 
commences within hours of graft insertion (10,11,54) 
and cells appear to follow the 'preprogrammed' mi-
gratory routes for their particular lineage (e.g. dendritic 
cell (55,56». During the first five days after surgery, 
leukocytes leave the graft and move to the spleen, 
lymph nodes, thymus and bone marrow (10,11). Two 
weeks later, donor leukocytes have undergone a second 
phase of movement and can be found in all other tissues 
examined throughout the recipient's body, including 
lymph nodes, thymus, bone marrow, tongue and heart 
(10,11). With the exception of transplants between a 
limited number of experimental animal strains, immu-
nosuppressive control is essential for the second phase 
of migration and the long-term survival of donor 
leukocytes (10,11), albeit at a 100v level (Fig_ 3a). Such 
migration is a gradual process and, with sequential 
monitoring, the gradual depletion and replacement (by 
host cells) of donor leukocytes within the allograft can 
be measured (Fig. 3b). 
When transplants arc performed without immuno-
suppression, the first stage of migration occurs as pre-
dicted. After reaching the lymphoid organs, however, 
the donor leukocytes arc progressively destroyed by 
rejection over a period of14 days (11). When immuno-
suppressive agents are used, the passenger leukocytes 
persist and redistribute to widespread organs, as indi-
cated above. The clinical data accumulated so far, using 
many different immunosuppressive regimes, strongly 
suggest that this effect is not drug-specifIC (4,6-9,57) 
(Table 2). Likewise, the permanent graft acceptance 
seen in experimental transplantation with every major 
imm unosuppressant introduced in the last 30 years also 
indicates that drugs merely act as permissive agents 
which allow migration to occur (3,8). 
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Fig. 2 Progressive development of an understanding of liver transplantation: (a) historical view; (b) realisation (in 1969) that 
the liver graft became a genetic composite (chimera); (c) proof in 1992 of systemic chimerism. Stars represent the exchange of 
cells between graft and host. 
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Fig. 3 Donor mononuclear cells appear in the blood of a 
human intestinal transplant recipient (a) and interstitial 
donor leukocytes are progressively replaced within the graft 
during the same time period (b). 
Table 2 Immunosuppressive regimes used in 44 long-term 
(10-30 years) survivors of liver transplantation. Data are 
expressed as means ± SD 
Amount 
No. of administered 
Group patients Drugs used (mg/day) 
1 12 Azathioprine 50 ± 26 
Prednisone 8.7 ± 3.2 
2 11 Cyclosporine 266 ± 132 
Prednisone 6.6 ± 3.4 
3 5 Cyclosporine 232 ± 132 
4 3 Azathioprine 58 ± 14 
Cyclosporine 158 ± 38 
Prednisone 9.2 ± 1.4 
5 2 Azathioprine 75,50 
6 J Azathioprine/ 
Cyclosporine 25,50/250,100 
7 1 FK 506/Prednisone 6/15 
8 1 FK506 10 
9 1 Prednisone 10 
10 5 Nothing 
Although the therapeutic agent used is not critical, it 
appears that prolonged continuous immunosuppres-
sion allows a greater percentage of donor leukocytes to 
survive than might otherwise be the case (11). As the 
majority of migrating cells are terminally differentiated 
(58), it is easy to understand how important it is that the 
maximum number of progenitor cells be allowed to 
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Fig. 4 Detection of chimerism by molecular HLA class II 
typing in various tissues after liver transplantation in a 
patient with type I Gaucher's disease. Southern blot 
analysis of DR I-specific amplification of the DNA extracted 
from small bowel, skin, bone marrow, blood and liver. The 
denatured DNA present on the nylon membrane was 
hybridised to a radioactively labelled DRl (donor) specific 
oligonucleotide probe (7001). In the case of the liver, only 
111 00 of the amplification product was used. 
engraft in the host to permit the indefinite survival of 
donor cells. Even so, in the m~ority of cases, the 
number of donor cells present after transplantation 
decreases to a small percentage (9-11), explaining the 
use of the term 'microchimerism', initially proposed by 
Liegcois ct al. (59). Although the number of cells is 
sometimes too small to detect by flow cytometry (Fig. 
3a), their presence can be demonstrated throughout the 
body after donor DNA amplification using either in situ 
hybridization or the polymerase chain reaction (Fig. 4 
and Table 3). 
Although different tissues contain very different 
quantities of nonparenchymal cells, cell migration is 
now thought to occur after the transplantation of all 
solid organs (4-9,11). The migrating cdls are ofmul-
tiple lineages and include B cells, T cells, NK cells, 
macrophages, mast cells and dendritic cells (10,11,58). 
These cells are postulated to modulate the recipient's 
Table 3 Microchimerism in liver 
allograft recipients according to Y-
chromosome detection with in situ 
hybridisation or peR. All studies 
were completed between April and Patient TP date 
June of 1992. In addition to Y- number (m/d/y) 
chromosome detection, underlined 
1 2118/73 patients were shown to demonstrate 
chimerism by immuuocytochemical 2 1121176 
detection of donor HLA alleles (in .3 1104/78 
cases 4, 6 and 9) or by peR 4 2126178 
molecular typing (all patients except 5 9/09178 
6 and 8) 6 3/09/80 
7 3/21/80 
8* 8/29/80 
9 12128/81 
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immune reaction and reduce donor-specific immune 
responsiveness (4-11). 
Donor-specific blood transfusion (DST) may confer 
some benefit on allograft survi val in a similar fashion, 
although the evidence supporting this concept has re-
cently become less compelling. In fact transfused 
patients may actually have reduced graft survival (60). 
Many mechanisms to explain the 'blood transfusion 
effect' have been proposed and although various 
cellular- and antibody-mediated mechanisms have been 
considered, there is as yet no single defined mechanism 
to account for the DST effect (61,62). 
Disruption of intercellular signalling concomitant 
with continuous donor alloantigen expression 
(Table 4) 
Since the pioneering experimental work on actively 
acquired tolerance in mice by Billingham ct al. (1), the 
induction of transplantation tolerance in humans (gen-
erally after bone marrow transplantation (BMT) has 
required ablation of the recipient's immune system 
with drugs or radiation, thus avoiding graft rejection. 
The transplanted bone marrow stem cells arc then able 
to mature throughout the recipient's immune system, 
including the thymus, rendering the host tolerant to 
donor alloantigens (63,64). Much of the seminal work 
concerning bone marrow chimerism has been per-
t()rmed by Sachs and his group. In studies on experi-
mental bone marrow transplantation in xenogeneic and 
allogeneic models, they have emphasised the import-
ance of mixed chimerism for the induction of allograft 
and xenograft tolerance (65,66). More recent studies 
show that such mixed chimerism, capable of inducing 
Tissue distribution 
Liver allograft Blood Lymph node Skin 
Age at 
TP (years) ISH peR peR ISH peR ISH peR 
3 +++ +++ + + + 
30 +++ +++ + + + + 
2 +++ +++ + + + + NT 
5 +++ +++ + + + + NT 
35 +++ +++ + + + + + 
29 NT +++ NT NT NT + 
34 +++ +++ + + 
28 +++ +++ + + + 
45 +++ +++ + + + + + 
TP = transplantation: ISH = in situ hybridisation: peR = polymerase chain 
reaction: NT = not tested. 
*This patient also tested positive for Y chromosome in the intestine with ISH and in 
multiple other tissues (including aortic wall). 
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Table 4 Mechanisms by which xenobiotics might promote the induction of allograft tolerance 
• Facilitate migration of 'passenger' leukocytes from donor-to-host and from host-to-donor. 
• Attenuate rejection, thereby preventing destruction of allogeneic donor antigen presenting cells in the recipient lymphoid 
and non-lymphoid tissues. 
• Allow B-cell activation (in response to surviving donor cell surface antigens) which may contribute to network control of 
the immune system. 
• Increase thymic accrual of dendritic cells allowing exposure of the immature host immune system to donor alloantigen. 
• Allow movement of immature thymocytes to the periphery resulting in further exposure of immature T cells to donor 
alloantigens. 
• Permit replication and widespread dispersal of the donor leukocyte population with consequent continuous presentation 
of donor alloantigen to the recipient immune system. 
• Inhibit the second signal required for activation of host lymphocytes presented with foreign alloantigen, thus promoting 
an anergic response. 
donor-specific tolerance, can be induced without mye-
loablatioll (53). 
Under immunosuppressive therapy, or without this 
condition in several experimental liver transplant 
models, donor leukocytes survive. The donor APe, 
particularly dendritic cells, but possibly also other lin-
eages, including activated B cells (10,67,68), may con-
tribute to the induction of tolerance by continuously 
presenting donor-MHC to the recipient as they interact 
with the recipient's immune system. Several factors are 
likcl y to be involved. 
Based on the immune network theory initially pro-
posed by Jerne (69-73), it is possible that anti-idiotypic 
clones of host T and 13 cells (anti-sclf), produced as part 
of the network response to dOllor alloantigen, may 
recognize a component of the class II MHC/T -cell 
receptor complex on the activated host CD4 (+) T cells 
and thereby control rejection (54). Development of 
such regulatory control would be dependent on a rejec-
tion response attenuated by careful pharmacological 
control. Excessive immunosuppression could be harm-
ful and inhibit tolerance induction by abrogating both 
the recipient respOllSe to donor and the replication of 
donor cells (54,59,74). The influence of antilympho-
cytic agents on T-cell development deserves separate 
comment. The powerful T -cell-directed immuno-
suppressants FK50() and CsA, both of which induce 
tolerance in rodents, also alter the thymic micro-
Ctlvironmt'llt in which T cells mature (75,76). As a 
result, these drugs inhibit thymocyte maturation and 
cause a dispersal of immature T cells into the periphery 
(77,78). During immunosuppression, thymic recruit-
ment of interdigitating dendritic cells also occurs (79). 
In the presence of a transplanted organ, both effects 
may increase the exposure of immature recipient T cells 
to donor APC - a process which closely parallels the 
concept of intrathymic antigen presentation which is 
used as the basis for allograft tolerance induction fol-
lowing intrathymic injection of donor cells (80,81). 
Furthermore, it has been demonstrated in such models 
that the presence of donor APC is essential for donor-
specific tolerance to occur (68,82,83). These data reas-
sert the importance of the chimeric state following 
organ transplantation in which the emigrant donor 
leukocytes may act as a 'vaccine' of donor MHC alloan-
tigen which affects the maturation of the recipient 
immune system. The result envisaged is similar to that 
seen after T-cell vaccination for the inhibition or pre-
vention of autoimmune disease (84). 
The B-cell component of the donor-derived leuko-
cytes Illay contribute to the induction of tolerance. 
Although not 'professional' APC, they have the ability 
to present antigen to T lymphocytes and induce unres-
ponsiveness in these cells (85). Furthermore, polyclonal 
B-cell activation is known to occur in sOllle experimen-
tal models of transplantation tolerance (86,87). This 
may contribute to an antibody-mediated component of 
the network control of rejection (54), a concept sup-
ported by early clinical reports of improved graft 
survival in patients with high levels of anti-Fab (anti-
idiotypic) antibodies (88,89). 
Finally, the two-signal model of lymphocyte acti-
vation initially proposed by Bretscher and Cohn pro-
vides further insight into possible mechanisms of 
tolerance induction (90). In this model, TCR occu-
pation alone does not induce clonal proliferation. In-
stead, a second signal (either secretion of a cytokine or 
expression of a costimulatory APC surface molecule 
such as B7/BB1 (91)) is required. The inhibition of 
APC function and APC-T-cell interaction that occurs 
with many immunosuppressants could block delivery 
of this second signal and perhaps induce T-cell anergy 
through the production of putative 'anergy proteins' 
and decreases in intracellular calcium within the T cells 
(91). The anergic state rna y be maintained by a defect in 
IL-2 accumulation in the presence of continuous anti-
genic stimulation supplied by the donor-derived APC 
(91,92). When the first and second signals arc transmit-
ted simultaneously, clonal proliferation occurs and re-
jection ensues. A prime candidate for second signal 
activation is the B7 ligand CD28, a T-cell surface 
molecule which promotes translation and stability of 
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Table 5 Features of six liver allograft recipients who had 
achieved drug-free graft tolerance 
Year Years 
Year drug drug Prednisone Liver 
Patient ofTP stopped free (mg/day) function 
1973 1982 10 Normal 
2 1974 1985 7 Normal 
3 1977 1987 5 Normal 
4 1978 1979 13 Normal 
5 1979 1981 11 Normal 
6 1980 1985 7 10 Failing" 
TP = transplantation 
*Rccurrent chronic active hepatitis secondary to hepatitis C 
virus was the biopsy-proven diagnosis from the graft 
hepatectomy specimen obtained at retransplantation. 
cytokine mRNA (including that of IL-2) (93). The 
continuous presence of donor MHC on leukocytes that 
havc migrated from the graft is likely to induce chronic 
TCR occupancy in any cells that do divide. This chro-
nic stimulation would be likely to generate more puta-
tive negativc regulators, thus reinforcing the anergic 
state. 
Stopping immunosuppressive therapy 
The idcal clinical situation would obviously be the 
routinc induction of donor-spccific tolerance after 
organ transplantation, as evidenced by in vitro donor-
specific hyporeactivity, followed by weaning from 
immullosuppressive medications. This would reduce 
exposure of the patient to the complications of immu-
nosupprcssion and the side effects of antirejection ther-
apy. But whcn can immunosuppressive treatment be 
stopped, if at all? 
Given the conccptual basis for tolerance induction 
outlined abovc, the absolute requircment for immuno-
suppressioll is that it is in place at the time of transplan-
tation to allow the establishment of a chimeric state. In 
many animal models of transplantation tolerance. drug 
therapy is only administered at or around the time of 
organ grafting; this is sufficient to induce both chimer-
ism and tolerancc, which arc thcn self-maintained. 
Although the problem is morc complex in humans, 
somc patients do achieve drug-free status after organ 
transplantation (Table 5). This has becn shown to occur 
between 2 months and 11 years postoperatively, but in 
an unreliable and unpredictable way (8,9). The ease 
with which immunosuppression can be stoppcd 
appears to be dependcnt on the type of organ trans-
planted. It has been shown in many experimental ani-
malmodc1s (34,94-99) and clinically (8,9,100) that liver 
grafts (which are rich in passenger leukocytes) arc much 
more pronc to induce tolerance than kidney or hcart 
grafts (with their fewer passenger leukocytes) when 
immunosuppression is discontinued. 
Although it is not known whcther thcre is an optimal 
time to stop immunosuppression, the introduction of 
FKS06 with its powerful ability to revcrse episodes of 
acute rejection (28) makes the withdrawal of immuno-
suppressive thcrapy a rcal possibility with significant 
inhcrent advantages for the transplant patient (101). 
Clearly however, it is prudent to wait until the recipicnt 
has been stable without rejection for some timc and has 
shown evidence of only minimal in vitro donor alloreac-
tivity, before any attempt is made to wean drug ther-
apy. A trial is currently underway at the University of 
Pittsburgh Mcdical Centre aimcd, ultimately, at re-
moving immunosuppressant therapy in patients with 
liver transplants who have been free of rejection for S 
years or more (8,101). The results of this study may 
have im portant implications for the future managemcnt 
of liver recipients, and perhaps recipients of other organ 
transplants as well. 
Clinical augmentation of the 'natural' chimeric 
state 
In an effort to augment the 'natural' chimerism that 
occurs after organ transplantation (caused by donor 
leukocytes of bone marrow origin), human recipients 
of whole organ grafts at this medical centre havc 
received the simple expedicnt of donor bone marrow 
infusion at the timc of transplantation. Therc has been 
no deviation from the standard initial immunosuppres-
sive regime (routine immunosuppression with FKS06 
and prednisone and without cytoablation) (102). The 
expectation was that the acccptance of organs less 
tolerogenic than the liver, such as the heart and kidney 
(or even thc liver itself) might be facilitated by aug-
menting the natural process of chimcrism with the 
infusion of donor bone marrow (4,6,8,9). 
The results to date are consistcnt with this hypoth-
esis. Sixtcen organ-bone marrow recipicnts (kidncy 
(n = 9), liver (n = 6; 3 with islets), heart (11 = 1)) have 
good graft function, 3-13 months postoperatively. All 
patients, exccpt one whose nearly complete HLA 
match precludes examination, show readily idcntifiable 
chimerism by flow cytometric anal ysis and corroborat-
ivc polymerasc chain rcaction quantitative testing. Rc-
jection occurred in ninc patients and graft-versus-host 
disease in two - both complications werc successfully 
trcated. This study rcconfirms previous warnings that 
chimerism is not synonymous with tolerance, but is 
only a necessary precondition for its dcvelopment 
(4,8,1 OJ). The pace of drug weaning, with the eventual 
goal of drug-frec tolerance, is being determined indi-
vidually for each patient with guidancc from serial tests 
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of ill pitro immune reactivity to donor and third party 
alloantigens. Most patients show evidence of evolving 
donor-specific hyporesponsivelless, however, none 
have yet achieved a drug-free state. These results corre-
late with those of Barber ct al. who, using the 'Monaco 
model' of adjuvant donor bone marrow administration 
(104), showed an increase in one-year renal allograft 
survival from 71 to 90% (105). The similar number of 
njection episodes seen in the bone marrow-treated and 
the control groups was a source of some concern to the 
authors, however, we feel that a controlled recipient 
response to donor plays a crucial part in the initiation of 
ultimate graft tolerance. 
Beyond an adjuvant role for whole organ transplan-
tation, it will be important to determine if MHC 
mismatched bone marrow engrafted under the above 
conditions can be used without an accompanying organ 
in patients whose disease can be corrected with a mixed 
chimeric state. The potential list of such indications is 
long (106), and is exemplified by the lysosomal enzyme 
deficiencies (7). 
Breaking tolerance with immunosuppressive 
agents 
The tolerant state envisaged after organ transplantation 
is an active phenomenon, with a constant but stable 
interaction between the donor and recipient at many 
different levels (11,54,58,70,73,87,107). Such stability 
requires positive recognition of donor with integration 
of host and recipient immune systems secondary to 
mutual stimulation (70) - an active process which does 
not appear to involve either clonal deletion or anergy 
(58). In effect, this active process by the donor-derived 
leukocytes is an incipient graft-versus-host (GVH) 
reaction which is thought to be essential for tolerance to 
occur (9,54). 
The stable and balanced chimerism that equates with 
tolerance may topple either towards graft rejection by 
the recipient or GVH disease mediated by donor-
derived cells (108). Although the topics of rejection and 
GVH reactivity are too large to address in this paper, 
some drug-related phenomena related to the breaking 
of tolerance arc important and will be addressed briefly. 
Even though the cessation of immunosuppression is 
a desirable goal, there is experimental evidence indi-
cating problems that may arise. In certain rat strain 
combinations for example, stable engraftment follow-
ing liver or small bowel transplantation is seen until 
immunosuppression is stopped; GVH disease then 
ensues with fatal results (109,110). In these phenotype 
combinations, the two immune systems are able to 
mutually coexist while being controlled by drugs, but 
donor cells can overpower those of the recipient after 
pharmacological control has been terminated 
(109,110). 
Notably, histocompatibility differences are not 
required for the development of GVH disease. Glazier 
ct al. were the first to describe a model of syngeneic 
GVH disease in adult rats after lethal irradiation, syn-
geneic bone marrow transplantation and a temporary, 
40-day period of CsA treatment (111). Although the 
pathogenesis of this disorder is not completely under-
stood, autoreactive T lymphocytes arc certainly in-
volved (112). These cells appear to be produced in a 
CsA-damaged thymus which cannot eliminate poten-
tiall y autoreactive lymphocytes during their differen-
tiation (113). A key factor ill the induction of this 
syndrome is the abolition of immune regulatory sys-
tems by a combination of irradiation and CsA (114). 
When normal mature T cells ~re allowed to remain in 
animals treated with CsA alone, the disease does not 
develop (24). 
In a recent clinical case, reminiscent of the tolerance 
breaking experiments described in a classic article by 
Billingham, Brent and Medawar (115), stored graft-
recipient bone marrow cells have been used to reverse 
graft-versus-host disease in a patient given a combined 
liver-(donor) bone marrow transplant. The tolerance 
breaking effect of the bone marrow infusion was in-
complete - this allowed control of the GVHD without 
~ttendant allograft rejection. The case was that of a 56-
year-old male with gastric leiomyosarcoma and liver 
metastases who underwent liver transplantation after 
upper abdominal exenteration (116). The patient 
received 5.5 Gy total lymphoid irradiation preoperati-
vely followed immediately postoperatively by 19 X 109 
110npurged donor bone marrow cells. During the next 
few weeks (in the presence of22-34% circulating donor 
phenotype lymphocytes), he developed a severe graft-
versus-host disease, with >80% skin involvement, 
which did not respond to changes in immunosuppres-
sion. On the 42nd and 43rd postoperative days, 2.83 X 
10H autologous stored bone marrow ce1ls were infused. 
Over the subsequent two weeks, while the donor 
phenotype lymphocytes decreased to .1% of total, the 
skin rash resolved and the patient was discharged with-
out evidence of rejection. 
Other preliminary data have also been reported on 
the deliberate breaking of tolerance in a clinical model 
(117). Because of the beneficial antitumor effect of 
GVH disease after experimental allogeneic BMT, a trial 
was conducted to evaluate whether GVH reactivity 
could be induced in humans with CsA therapy. Study-
ing a group of patients with lymphoma in resistant 
relapse, Jones ct al. demonstrated that moderately 
severe GVH disease could indeed be induced in patients 
undergoing autologous BMT following total body 
irradiation and CsA therapy (117). Furthermore, pre-
liminary results suggested that the presence of GVH 
disease in these patients promoted a significant antitu-
mour effect (118). 
Conclusion 
The dcvelopment of modern immunosuppressive regi-
mens largcl y accounts for current successes in alloge-
neic organ transplantation. Although the mechanism of 
action of the divcrse range of immunosuppressivc 
agents in current use varies greatly, it appears that they 
have a common potential to induce graft tolerancc. 
Adequate, but not complete immunosuppression is 
now believed to permit donor-derived leukocytes to 
migrate from the graft, disperse widely in thc recipi-
ent's tissues and establish multilineage microchimer-
ism. Donor APe thcn continuously represent donor 
alloantigens to the recipient immune system. Under 
pharmacological immunosuppressive therapy, a mini-
mal rejection process develops. Rejection, however, is 
limited by immunosuppression and may be converted 
to an activc, network-regulated tolerant state. 
In some organ-transplant patients, it is possible to 
cease immunosuppressive therapy and donor-specific 
tolerance is maintained spontaneously. Investigations 
are currently underway to define which organ allograft 
recipients are suitable candidates for this strategic 
approach without invoking excessive risk to the patient 
of developing graft rejection or GVH disease. Further 
investigations are examining whether the synchronous 
transplantation of donor bone marrow combined with 
a solid organ into recipients receiving routine immuno-
suppression, without cytoablation, can augment the 
chimeric state and facilitate allograft acceptance. 
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